The number of antibody-drug conjugates (ADC) currently in clinical trials exceeds sixty, reflecting the therapeutic interest of this class of formulations. ADCs are designed to bind to an internalizing cancer cell receptor leading to uptake of the ADC and subsequent intracellular release of the drug by enzymes, thiols or lysosomal pH. While particularly efficient for
T cells expressing chimeric antigen receptors (CAR T) are particularly promising for the treatment of refractory cancers. While Kymriah and Yescarta are FDA-approved for B-cell malignancies, safety and efficacy concerns remain across the cell therapy industry. Severe cytokine release syndrome triggered by T cell infusion is one of the urgent CAR T related downsides that needs
Last week, Akron participated in the Phacilitate Automation Special Interest Group, a gathering of key industry stakeholders aimed at fostering discussion around the main challenges associated with developing and implementing automation solutions in an industry characterized by process variety and complexity, as well as the need to ensure data integrity. According to Dr. Rodney Rietze,
Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan-Kettering Cancer Center, recently sat down with Jennifer Adair, PhD, of the Fred Hutchinson Cancer Research Center to discuss the remarkable progress being made in the field of chimeric antigen receptor (CAR) engineered T-cell therapies to treat cancer. CAR T-cell therapies consist
A considerable volume of research in the field of cancer therapy focuses on the design and evaluation of drug delivery systems that efficiently target tumor cells while minimizing drug doses and damage to healthy tissues. Delivery systems with magnetic properties are a recent addition to the repertoire. In a study conducted by a group of
Last week, the Akron team joined more than 1,600 participants from 50+ countries at the annual meeting of the International Society for Cell and Gene Therapy (ISCT) in Montreal. Chaired by David DiGiusto, PhD (Stanford School of Medicine), Sarah Nikiforow, MD, PhD (Dana Farber Cancer Institute), and Denis-Claude Roy, MD, FRCPC (Hôpital Maisonneuve-Rosemont), the meeting
Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) have terrible prognoses and novel cell therapies provide a glimmer of hope. While the CAR T therapy known as Kymriah led to complete remission in over 90% of patients with advanced acute lymphoblastic leukemia (ALL), only 26% of CLL patients responded to it in clinical trials.
Riding the commercial approvals of two CAR T immunotherapies last year, the energized regenerative medicine community will be coming together in Montreal for the Annual ISCT Global Meeting and Exhibition from Wednesday May 2nd through Saturday May 5th. Don’t miss Dr. Claudia Zylberberg, CEO of Akron Biotech, during the Quality & Operations Track speaking about
Diffuse intrinsic pontine glioma (DIPG) with mutated histone H3 K27M is an extremely aggressive, universally fatal pediatric brain cancer. DIPG affects a few hundred children across the country each year and typically exhibits rapid clinical onset and progression with 90% mortality rate within 18 months of presentation. There is no cure and no effective treatment.
Akron Biotech was proud to be a sponsor of this year’s Innate Killer Summit held in San Diego, California. The Innate Killer Summit is the leading, dedicated end-to-end meeting serving as a catalyst to ensure successful clinical and commercial translation of NK cell immunotherapies. The most current and advanced clinical data was presented as well
